Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zasocitinib in Moderately to Severely Active Ulcerative Colitis and Crohn's Disease
NCT06764615Phase 2Recruiting
- Sponsor
- Takeda
- Start
- May 2025
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of zasocitinib in Crohn's disease, ulcerative colitis (UC), sponsored by Takeda. Started May 2025; status: recruiting.
02
Drugs
zasocitinib
03
Conditions
Crohn's diseaseulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06764615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06764615.